An interventional study of 18F-DOPA in Medullary Thyroid Cancer, sponsored by Institut Claudius Regaud. Completed at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Institut Claudius Regaud · Not applicable, Interventional, and Diagnostic
The aim of the trial is to study a radiating diagnosis agent used in post surgery when the biological assessment highlighted a residual disease.
This is an inter-regional multicentric, prospective study evaluating the benefit of PET F-DOPA imaging in involved node detection compared to standard imaging assessment in patient with medullary thyroid cancer.
The purpose of the study is to evaluate the impact and performance of a new PET / CT (computerized tomography ) tracer targeting dopamine receptor in patient with residual ganglionar biological disease after initial surgery of medullary thyroid cancer compared to standard imaging.
Obtained data will be compared to the "gold standard" based on :
65 studies on the registry are indexed under Carcinoma, Medullary; 17 are open to participants now.
This study's enrollment of 24 is below the median of 41 across 49 interventional studies indexed under Carcinoma, Medullary.
Browse Carcinoma, Medullary studies →Institut Claudius Regaud is the lead sponsor of 117 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
18F-DOPA will be administered with an activity of 1.5-4 MBq/kg (MegaBecquerel) in the IV (Intra venous) tubing to decrease the extravasation risk and tracer lymphatic migration. The injection site will be distant from pathologic area (forearm). PET CT exam will start 10 min after tracer injection and will cover the whole body (10 to 30 min). Other series of images will be done 50 min after tracer injection. Images will be interpreted.
Other: 18F-DOPA
Injection of 18F-DOPA and PET / CT-scan assessment
Relative rate of TRUE positive nodes with PET F-DOPA compared to standard imaging assessment.
Analysis will be performed by node.
Time frame: up to 3 years
Relative rate of TRUE positive nodes with PET F-DOPA compared to standard imaging assessment.
Analysis will be performed by patient.
Time frame: up to 3 years
Relative rate of FALSE positive nodes with PET F-DOPA compared to standard imaging assessment.
Analyses will be performed by patient and by node.
Time frame: up to 3 years
Relative rate of TRUE positive and FALSE metastasis with PET F-DOPA compared to standard imaging assessment.
Analyses will be performed by patient and by metastasis.
Time frame: up to 3 years
Modification rate of patient's care after PET F-DOPA exam.
Comparison of the modification of care (orientation to a surgery or a surveillance) decided after standard imaging assessment following result of TEP-FDOPA exam.
Time frame: up to 3 years
The concordance between the PET F-DOPA results of each centre and centralized review.
Concordance (centre / reviewer) of PET F-DOPA result interpretation will be evaluated.
Time frame: up to 3 years
Plan to share: Undecided
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Claudius Regaud